Sino Biopharmaceutical Limited (1177.HK) earnings: next date, last results and guidance
When is Sino Biopharmaceutical Limited's next earnings date, and what were its last results?
Last results
- SalesRMB19.4 billion+11 %
Sino Biopharmaceutical Limited's own figures for the half-year to June 2026. Growth is on a year earlier.
New accounts get one company's ready report free. No card.
Executive summary + 8 chapters · 20,071 words · 158 sources
Sino Biopharmaceutical Limited guidance: what does it expect for the year to December 2026?
Management historically gave no quarterly or annual financial guidance. Its current targets include a 50% share of 2026 revenue from innovative drugs and out-licensing, with gross margin of 80%. It also targets 27 innovative products in 2026 and 30 launches by 2027. Seven siRNA candidates are expected to submit applications to begin human testing between the second half of 2026 and the first half of 2027. The company met its 2025 innovative-product target, reporting 47.8% against 45%.
Share of revenue from innovative drugs and out-license
50.0%Year to Dec 2026 · given 2026-08-19
R&D expenses ratio
19.0%Year to Dec 2026 · given 2026-08-19
Guidance is management's forecast of what it expects to report, usually a range.
Did Sino Biopharmaceutical Limited keep its past promise?
An innovative product is a newer medicine developed or acquired through research, rather than an established generic copy. Sino Biopharm forecast that such products would reach 45% of 2025 revenue and reported 47.8%. That shows the sales-mix target was met, but not the products’ margins, risks, cash generation or effect on earnings per share.
What is Sino Biopharmaceutical Limited's revenue and profit trend?
The latest reported period is the six months to June 2026. Revenue rose 10.6% year on year to RMB19.44 billion. Gross margin reached 83.0%, up from 82.5%. Net income was RMB3.43 billion, while diluted EPS was RMB0.19.
For the six months to June 2026, revenue rose 10.6% from the same period of 2025, gross margin increased to 83.0% from 82.5%, and innovative-drug sales grew faster than group revenue. The main new ingredient was out-licensing: Sino granted Sanofi, a pharmaceutical partner, rights to develop, manufacture and commercialize rovadicitinib.
What should you watch in Sino Biopharmaceutical Limited's next release?
The full-year 2026 result should separate innovative-drug sales from out-licensing income. A rising combined share driven mainly by a deal would mean something different from sustained prescription growth.
Questions about Sino Biopharmaceutical Limited (1177.HK) earnings
Are Sino Biopharmaceutical Limited's latest earnings out?
Yes. Sino Biopharmaceutical Limited has reported the half-year to June 2026.
Is Sino Biopharmaceutical Limited expected to beat earnings?
Our report makes no call on that. Management's guidance: Share of revenue from innovative drugs and out-license, Year to Dec 2026: 50.0%.
Where could Sino Biopharmaceutical Limited stock be by 2029?
Our report's forecast is HK$6.90 a share by November 2029, from the HK$5.60 close of November 6, 2026. Sino Biopharmaceutical Limited stock forecast →
More on Sino Biopharmaceutical Limited (1177.HK)
Sino Biopharmaceutical Limited and its rivals
Sino Biopharmaceutical Limited's own filings
This page gives the results. The report gives the reasons.
The full report: an executive summary and 8 chapters, 20,071 words, 52 tables. Its first page opens here, no account needed.
How it is made: AI reads Sino Biopharmaceutical Limited's filings, writes the report, checks the numbers against them and cites each source, 158 in this one. How we work · Corrections
Read the full report freeNew accounts get one company's ready report free. No card.
Information only, not investment advice. The next results date is an expectation until Sino Biopharmaceutical Limited confirms it. Prices are those of the date shown.